(Schizophrenia) – Forecast and Market Analysis to 2022
Total Page:16
File Type:pdf, Size:1020Kb
REFERENCE CODE GDHC367DFR | PUBLICATION DATE FEBRUARY 2014 BREXPIPRAZOLE (SCHIZOPHRENIA) – FORECAST AND MARKET ANALYSIS TO 2022 BREXPIPRAZOLE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Table below provides a summary of the key May have an effect on negative symptoms. metrics for Brexpiprazole in the seven major Otsuka has a strong presence in the pharmaceutical markets during the forecast period schizophrenia drug market. upto 2022. Conversely, the major barriers for the growth of Brexpiprazole : Key Metrics in the Seven Major Brexpiprazole in the schizophrenia market include: Pharmaceutical Markets, 2012–2022 Key Events (2012-2022) Level of Impact Higher cost of therapy compared to older Anticipated launch of Brexpiprazole in ↑↑↑ medications. US(2015) Anticipated launch of Brexpiprazole in ↑↑ Requires daily oral dosing. Japan (2016) 2022 Market Sales The figure below illustrates Brexpiprazole sales in US $1,648.9m the 7MM by region during the forecast period. 5EU $28.4m Japan $105.8m Sales for Brexpiprazole by Region, 2022 7MM $1,783.1m 5.9% 1.6% 2022 Source: GlobalData. Total : $1,783.1m 7MM = US, France, Germany, Italy, Spain, UK, Japan; 5EU = France, Germany, Italy, Spain, UK US Sales of Brexpiprazole in Global Schizophrenia 5EU Market, 2022 Japan Brexpiprazole sales are expected to increase from $176.2 million upon launch in 2015 to $1,783.1 92.5% million in 2022. Source: GlobalData. Major growth drivers for Brexpiprazole in the Schizophrenia market over the forecast period include: Structurally similar to Otsuka’s Abilify, the current market leader in the schizophrenia drug market. Improved tolerability and similar efficacy to Abilify demonstrated in clinical trials. Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022 2 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form. BREXPIPRAZOLE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary What Do the Physicians Think? in terms of epidemiology. But they have increased in terms of rate of prescribing because the “Unfortunately there is really nothing out there diagnosis has expanded to which these which would give me confidence that we will have medications are directed to.” something reasonably effective in the next several years. We are probably coming to one set of [EU] KOL, November 2013 results very soon, probably sometime early next “[We] treat them according to the presenting year or maybe the spring of next year, the syndrome. And even more specifically – in terms of glutamatergic compounds.” the positive symptoms, depression, affective [US] KOL, October 2013 symptoms, or cognitive symptoms, negative symptoms – they will be cueing in much more on “There isn’t that much coming out these days, so that rather than on the label of, ‘Is this that’s a fact which many of us have actually agreed schizoaffective, is it bipolar, is it a schizophrenic on is a major, major issue. We’ve had discussions patient?’ I think once it gets down to medications, with pharmaceutical companies as a group of then it gets much simpler. These discussions do pharmacologically oriented and research-oriented not reach into the medication decision-making psychiatrists and say, ‘Please come back and process.” reactivate your research and development sections and divisions. Don’t desert this group of patients, [EU] KOL, December 2013 because we need better drugs.’ There’s no doubt “Going systematically, you have the glutamatergic about it.” compounds, you have nicotinic acid agonists, you [US] KOL, September 2013 have the me-too drugs, which are the D2/5-HT2 antagonists, and of those we have plenty, we don’t “If you look at the utilization patterns of need anything more, that mechanism of action is antipsychotics you do see that once the atypicals entirely taken care of, so to speak.” were introduced, the usage of these medications went up significantly. And this is not at all because [US] KOL October, 2013 there are more schizophrenic patients around. In fact, schizophrenia has actually decreased slightly Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022 3 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form. BREXPIPRAZOLE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Table of Contents 1 Table of Contents 1 Table of Contents .......................................................................................................................... 4 1.1 List of Tables......................................................................................................................... 7 1.2 List of Figures ....................................................................................................................... 7 2 Introduction ................................................................................................................................... 8 2.1 Catalyst ................................................................................................................................. 8 2.2 Related Reports .................................................................................................................... 9 2.3 Upcoming Reports .............................................................................................................. 10 3 Disease Overview ....................................................................................................................... 11 3.1 Etiology and Pathophysiology ............................................................................................. 11 3.1.1 Etiology ........................................................................................................................... 11 3.1.2 Pathophysiology ............................................................................................................. 12 3.2 Symptoms ........................................................................................................................... 13 4 Disease Management.................................................................................................................. 14 4.1 Diagnosis ............................................................................................................................ 14 4.1.1 Subjective Assessments ................................................................................................. 15 4.1.2 Disease Subtypes ........................................................................................................... 16 4.2 Treatment Overview ............................................................................................................ 18 4.2.1 Treatment of Acute Agitation Associated with Schizophrenia .......................................... 21 4.2.2 Maintenance Treatment of Schizophrenia ....................................................................... 22 5 Competitive Assessment ............................................................................................................. 23 5.1 Overview ............................................................................................................................. 23 Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022 4 © GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form. BREXPIPRAZOLE (SCHIZOPHRENIA) - FORECAST AND MARKET ANALYSIS TO 2022 Table of Contents 5.2 Strategic Competitor Assessment ....................................................................................... 24 6 Opportunity and Unmet Need ...................................................................................................... 26 6.1 Unmet Needs Overview ...................................................................................................... 26 6.1.1 Public Awareness ........................................................................................................... 27 6.1.2 Early Diagnosis and Treatment ....................................................................................... 29 6.1.3 Long-Acting and Advanced Drug Delivery Systems ........................................................ 30 6.1.4 Effective Management of Negative and Cognitive Symptom Domains ............................ 31 6.2 Gap Analysis ....................................................................................................................... 32 6.2.1 Long-Acting Drug Delivery .............................................................................................. 33 6.2.2 Treatment of Negative and Cognitive Symptoms ............................................................ 33 7 Pipeline Assessment ................................................................................................................... 34 7.1 Overview ............................................................................................................................. 34 7.2 Early-Stage Pipeline Assessment ....................................................................................... 34 7.3 Novel Therapeutic Approaches ........................................................................................... 35 7.3.1 Negative Symptoms ........................................................................................................ 36 7.3.2 Cognitive Symptoms ......................................................................................................